LifeMD Expands Insurance Acceptance to Medicare Beneficiaries for Qualifying Virtual Primary Care, Including in its Weight Loss Programs
LifeMD (NASDAQ: LFMD) has announced expanded insurance acceptance to Medicare beneficiaries for qualifying virtual primary care services, including weight management programs. Initially available to over 21 million Medicare Part B beneficiaries in 26 states, the company plans to extend access across 49 states by Q2 end, potentially serving more than 60 million Medicare beneficiaries.
The expansion follows two years of investment in operational readiness and regulatory compliance. The company highlights that approximately 75% of Medicare beneficiaries are overweight, obese, or managing at least one cardiometabolic condition. While Medicare Part B covers virtual consultations for obesity and chronic conditions when medically necessary, Medicare Part D coverage for GLP-1 medications is currently to specific conditions.
Through the LifeMD platform, customers will have access to synchronous medical care, urgent prescriptions and refills, and laboratory services through Quest and Labcorp. This initiative aligns with LifeMD's strategy to diversify payor mix and strengthen recurring revenue streams.
LifeMD (NASDAQ: LFMD) ha annunciato l'espansione dell'accettazione delle assicurazioni per i beneficiari di Medicare, includendo servizi qualificati di assistenza primaria virtuale, come i programmi per la gestione del peso. Inizialmente disponibile per oltre 21 milioni di beneficiari di Medicare Parte B in 26 stati, l'azienda prevede di estendere l'accesso a 49 stati entro la fine del secondo trimestre, potenzialmente raggiungendo più di 60 milioni di beneficiari Medicare.
Questa espansione segue due anni di investimenti nella preparazione operativa e nella conformità normativa. L'azienda sottolinea che circa il 75% dei beneficiari Medicare è in sovrappeso, obeso o gestisce almeno una condizione cardiometabolica. Sebbene Medicare Parte B copra le consulenze virtuali per obesità e condizioni croniche quando necessarie dal punto di vista medico, la copertura Medicare Parte D per i farmaci GLP-1 è attualmente limitata a condizioni specifiche.
Attraverso la piattaforma LifeMD, i clienti avranno accesso a cure mediche sincrone, prescrizioni urgenti e rinnovi, oltre a servizi di laboratorio tramite Quest e Labcorp. Questa iniziativa è in linea con la strategia di LifeMD di diversificare il mix di pagatori e rafforzare le entrate ricorrenti.
LifeMD (NASDAQ: LFMD) ha anunciado la ampliación de la aceptación de seguros para beneficiarios de Medicare en servicios calificados de atención primaria virtual, incluidos programas de manejo de peso. Inicialmente disponible para más de 21 millones de beneficiarios de Medicare Parte B en 26 estados, la compañía planea extender el acceso a 49 estados para finales del segundo trimestre, potencialmente atendiendo a más de 60 millones de beneficiarios de Medicare.
Esta expansión sigue a dos años de inversión en preparación operativa y cumplimiento regulatorio. La empresa destaca que aproximadamente el 75% de los beneficiarios de Medicare tienen sobrepeso, obesidad o manejan al menos una condición cardiometabólica. Aunque Medicare Parte B cubre consultas virtuales para obesidad y condiciones crónicas cuando son médicamente necesarias, la cobertura de Medicare Parte D para medicamentos GLP-1 está actualmente limitada a condiciones específicas.
A través de la plataforma LifeMD, los clientes tendrán acceso a atención médica sincrónica, recetas urgentes y renovaciones, y servicios de laboratorio mediante Quest y Labcorp. Esta iniciativa está alineada con la estrategia de LifeMD de diversificar la mezcla de pagadores y fortalecer las fuentes de ingresos recurrentes.
LifeMD (NASDAQ: LFMD)는 체중 관리 프로그램을 포함한 자격을 갖춘 가상 1차 진료 서비스에 대해 메디케어 수혜자에 대한 보험 수용 범위를 확대했다고 발표했습니다. 처음에는 26개 주의 2100만 명 이상의 메디케어 파트 B 수혜자를 대상으로 제공되며, 회사는 2분기 말까지 49개 주로 확대하여 6000만 명 이상의 메디케어 수혜자에게 서비스를 제공할 계획입니다.
이번 확장은 2년간의 운영 준비 및 규제 준수 투자에 따른 결과입니다. 회사는 메디케어 수혜자의 약 75%가 과체중, 비만이거나 최소한 하나의 심장대사 질환을 관리하고 있다고 강조합니다. 메디케어 파트 B는 비만 및 만성 질환에 대해 의학적으로 필요할 때 가상 상담을 보장하지만, 메디케어 파트 D의 GLP-1 약물 보장은 현재 특정 조건에 한정되어 있습니다.
LifeMD 플랫폼을 통해 고객은 동기식 의료 서비스, 긴급 처방 및 재처방, 그리고 Quest와 Labcorp를 통한 실험실 서비스를 이용할 수 있습니다. 이 이니셔티브는 LifeMD의 지불자 구성 다변화 및 반복 수익 강화 전략과 일치합니다.
LifeMD (NASDAQ : LFMD) a annoncé l'élargissement de l'acceptation des assurances pour les bénéficiaires de Medicare concernant les services qualifiés de soins primaires virtuels, y compris les programmes de gestion du poids. Initialement disponible pour plus de 21 millions de bénéficiaires de Medicare Partie B dans 26 États, la société prévoit d'étendre l'accès à 49 États d'ici la fin du deuxième trimestre, desservant potentiellement plus de 60 millions de bénéficiaires Medicare.
Cette expansion fait suite à deux années d'investissements dans la préparation opérationnelle et la conformité réglementaire. La société souligne qu'environ 75 % des bénéficiaires de Medicare sont en surpoids, obèses ou gèrent au moins une condition cardiométabolique. Bien que Medicare Partie B couvre les consultations virtuelles pour l'obésité et les maladies chroniques lorsque c'est médicalement nécessaire, la couverture Medicare Partie D pour les médicaments GLP-1 est actuellement limitée à certaines conditions spécifiques.
Via la plateforme LifeMD, les clients auront accès à des soins médicaux synchrones, des prescriptions urgentes et leurs renouvellements, ainsi qu'à des services de laboratoire via Quest et Labcorp. Cette initiative s'inscrit dans la stratégie de LifeMD visant à diversifier le mix des payeurs et à renforcer les revenus récurrents.
LifeMD (NASDAQ: LFMD) hat die erweiterte Versicherungsakzeptanz für Medicare-Empfänger bei qualifizierten virtuellen hausärztlichen Leistungen, einschließlich Gewichtsmanagement-Programmen, angekündigt. Anfangs verfügbar für über 21 Millionen Medicare Part B-Empfänger in 26 Bundesstaaten, plant das Unternehmen, den Zugang bis Ende des zweiten Quartals auf 49 Bundesstaaten auszuweiten und damit potenziell mehr als 60 Millionen Medicare-Empfänger zu erreichen.
Die Erweiterung folgt auf zwei Jahre Investitionen in betriebliche Bereitschaft und regulatorische Compliance. Das Unternehmen hebt hervor, dass etwa 75 % der Medicare-Empfänger übergewichtig, fettleibig sind oder mindestens eine kardiometabolische Erkrankung behandeln. Während Medicare Part B virtuelle Konsultationen bei Adipositas und chronischen Erkrankungen bei medizinischer Notwendigkeit abdeckt, ist die Medicare Part D-Abdeckung für GLP-1-Medikamente derzeit auf bestimmte Bedingungen beschränkt.
Über die LifeMD-Plattform erhalten Kunden Zugang zu synchroner medizinischer Versorgung, dringenden Rezepten und Nachfüllungen sowie Laborleistungen über Quest und Labcorp. Diese Initiative steht im Einklang mit LifeMDs Strategie, die Zahlungsträger-Mischung zu diversifizieren und wiederkehrende Einnahmen zu stärken.
- Expansion to serve 21 million Medicare Part B beneficiaries, with potential growth to 60 million
- Strategic diversification of payor mix and strengthening of recurring revenue streams
- Partnership with major lab services providers Quest and Labcorp
- Targeting large addressable market with 75% of Medicare beneficiaries being overweight or having cardiometabolic conditions
- Medicare Part D coverage for GLP-1 medications restricts potential revenue from weight management programs
- Current Medicare telehealth flexibilities only guaranteed through September 2025
Insights
LifeMD's Medicare acceptance significantly expands market reach and diversifies revenue streams, positioning for growth in telehealth and weight management.
LifeMD's strategic expansion to accept Medicare for qualifying virtual primary care represents a substantial market opportunity. Initially reaching over 21 million Medicare Part B beneficiaries across 26 states and projected to expand to 60+ million beneficiaries across 49 states by Q2's end, this move dramatically enlarges their addressable market.
The economics are particularly compelling given that approximately 75% of Medicare beneficiaries are overweight, obese, or managing cardiometabolic conditions - precisely the demographic LifeMD's services target. This creates a significant revenue opportunity in an underserved market segment.
This expansion marks a pivotal shift in LifeMD's business model, diversifying beyond direct-to-consumer payments toward institutional reimbursement. This payor diversification should strengthen recurring revenue streams and potentially reduce customer acquisition costs through institutional channels.
The timing is particularly strategic with Medicare telehealth flexibilities extended through September 2025 and telehealth utilization among Medicare beneficiaries running nearly twice pre-pandemic levels (12.7% adoption rate). This sustained demand signals a permanent shift in care delivery preferences.
While current Medicare Part D coverage for GLP-1 medications remains , the noted bipartisan support for broader coverage represents a meaningful future catalyst. Should Medicare expand GLP-1 coverage, LifeMD would be ideally positioned with its virtual care infrastructure already Medicare-approved and operational.
This initiative follows two years of investment in operational readiness and compliance, suggesting thoughtful preparation rather than opportunistic pivoting. The systematic state-by-state rollout indicates a methodical scaling strategy focused on sustainable growth.
LifeMD's Medicare acceptance creates immediate revenue opportunity while strategically positioning for future telehealth policy and GLP-1 coverage expansion.
LifeMD's Medicare expansion addresses a critical access gap in American healthcare. With many Medicare beneficiaries lacking convenient primary care access—particularly in rural and underserved areas—this virtual care initiative directly tackles a persistent healthcare disparity problem.
The regulatory timing couldn't be better. The extension of Medicare Telehealth Flexibilities through September 2025 provides a stable policy foundation, while the American Telemedicine Association's note about Congressional support for permanent telehealth provisions suggests favorable long-term regulatory dynamics.
The two-year preparation period focused on operational readiness and regulatory compliance demonstrates LifeMD's commitment to properly serving the Medicare population. This careful approach significantly reduces execution and compliance risks that often plague healthcare innovations.
The current limitations on Medicare Part D coverage for GLP-1 medications present both challenges and opportunities. While coverage is primarily restricted to specific cardiovascular conditions and obstructive sleep apnea, bipartisan support for expanded access creates potential for policy evolution. LifeMD is wisely building the infrastructure and patient relationships now to capitalize on any future coverage expansion.
The 12.7% telehealth adoption rate among traditional Medicare beneficiaries—nearly double pre-pandemic levels—indicates sustained demand that contradicts earlier predictions of telehealth usage returning to baseline. This persistence speaks to genuine patient preference rather than merely pandemic-driven necessity.
By offering synchronized medical care, urgent prescriptions, and laboratory services through established partners like Quest and Labcorp, LifeMD has created a comprehensive virtual care ecosystem that mirrors traditional care delivery while improving convenience and accessibility.
LifeMD’s virtual care services now available to over 21 million Medicare Part B beneficiaries in 26 states, with 49-state access to qualifying services expected by the end of Q2
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 million Medicare Part B beneficiaries in 26 states, the company expects to expand access to medically necessary services for more than 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states anticipated by the end of the second quarter.
"We are proud to announce that LifeMD now accepts Medicare Fee-For-Service for qualifying virtual primary care, including such care provided in our weight management program – an important step forward in expanding access to essential care for older Americans. This launch follows two years of focused investment in operational readiness and regulatory compliance, positioning LifeMD to serve the growing Medicare population with confidence and at scale,” said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD.
“A significant portion of the Medicare population lacks convenient access to a primary care provider – especially in rural or underserved areas – making it difficult for older adults to receive timely, preventive care. At the same time, approximately
“Virtual consultations for patients with obesity and other chronic conditions are covered by Medicare Part B when medically necessary, yet Medicare Part D coverage for GLP-1 medications is currently generally limited to patients with cardiovascular conditions and obstructive sleep apnea, in the case of Zepbound®, among others,” he added. “Despite this, recent polls have shown overwhelming bipartisan support for Medicare and Medicaid coverage of GLP-1 drugs. We remain optimistic that a near-term solution will emerge to enable broader access to these life-saving medications.”
Recent legislation authorized an extension of Medicare Telehealth Flexibilities through September 30, 2025. Under this extension, Medicare beneficiaries can continue to receive telehealth services from a wide range of locations, including from their home. According to the American Telemedicine Association, Congress and the current administration have stated their support for a permanent solution to reestablish all telehealth provisions. According to KFF, at the end of 2023,
Customers using the LifeMD platform will have access to synchronous medical care, urgent prescriptions and refills, and laboratory services through Quest and Labcorp.
This expansion of acceptance of insurance to Medicare aligns with LifeMD’s long-term strategy to diversify payor mix, strengthen recurring revenue streams, and address underserved populations through scalable, technology-driven care delivery. As telehealth adoption accelerates, LifeMD is well-positioned to capture meaningful share within the growing Medicare market.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a 22,500-square-foot affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact
Jessica Friedeman, Chief Marketing Officer
press@lifemd.com
FAQ
What is the scope of LifeMD's Medicare coverage expansion announced in April 2025?
Does Medicare cover GLP-1 medications through LifeMD's virtual care platform?
What services will Medicare beneficiaries access through LifeMD's platform?
How long will Medicare telehealth flexibilities remain in effect for LFMD services?
What percentage of Medicare beneficiaries used telehealth services at the end of 2023?
